Agosti Marcello Pignagnoli Sells 22,957 Shares of Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Agosti Marcello Pignagnoli sold 22,957 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $392,564.70. Following the completion of the sale, the insider directly owned 176,977 shares of the company’s stock, valued at $3,026,306.70. The trade was a 11.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

NYSE TAK opened at $17.41 on Friday. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a 52-week low of $12.99 and a 52-week high of $18.90. The business’s 50-day moving average price is $16.53 and its 200 day moving average price is $17.14. The firm has a market cap of $55.77 billion, a P/E ratio of 51.19 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. The firm had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%. On average, equities research analysts expect that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Key Headlines Impacting Takeda Pharmaceutical

Here are the key news stories impacting Takeda Pharmaceutical this week:

• Positive Sentiment: The tax-related nature of the transactions reduces their significance as a signal of deteriorating management confidence. Insiders continued to retain substantial positions after selling, including CEO Julie So-Young Kim, who retained 391,489 shares, and Andrew Stewart Plump, who retained 766,569 shares. Takeda insider sales report
• Neutral Sentiment: Analyst views remain mixed, with two Buy ratings, one Hold and one Sell, producing a consensus rating of “Hold.” Institutional ownership is relatively limited at 9.17%, although several funds recently increased their positions. Takeda stock analysis
• Neutral Sentiment: Takeda’s latest reported quarter included $0.56 in EPS and $6.90 billion in revenue. Analysts expect approximately $3.01 in earnings per share for the current year, providing a fundamental backdrop for the stock as it trades near its 12-month high. Takeda financial data
• Negative Sentiment: Multiple insiders sold a combined 444,100 shares for approximately $7.59 million at an average price of $17.10. The sellers included CEO Julie So-Young Kim, General Counsel Natalie Anne Marie Furney, Andrew Stewart Plump and other executives; individual ownership reductions ranged from 5.9% to 18.5%. The volume and seniority of the sellers may weigh on sentiment, even though the sales were made for tax purposes. SEC insider filing

Institutional Investors Weigh In On Takeda Pharmaceutical

Institutional investors have recently added to or reduced their stakes in the business. Capital Research Global Investors increased its position in Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock worth $210,259,000 after purchasing an additional 82,643 shares during the period. UBS Group AG raised its stake in shares of Takeda Pharmaceutical by 46.4% during the 3rd quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after buying an additional 1,869,323 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in shares of Takeda Pharmaceutical by 100.9% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after buying an additional 2,854,069 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after buying an additional 370,800 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on TAK shares. Weiss Ratings lowered Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Zacks Research upgraded shares of Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.